Designing ctDNA-Based Interventional Clinical Trials: A Framework for Oncology
This concise review from Genome Medicine provides a framework for incorporating ctDNA into interventional clinical trial design. The authors discuss ctDNA applications in detecting minimal residual disease, selecting patients for tailored treatments, and identifying mechanisms of response or resistance. The paper offers practical guidance for trialists on endpoint selection, sampling strategies, and analytical considerations when using ctDNA as a decision-making tool in prospective studies.
The original study
Designing circulating tumor DNA-based interventional clinical trials in oncology.
- Authors
- Araujo DV, Bratman SV, Siu LL
- Journal
- Genome medicine
- Type
- Journal Article, Research Support, Non-U.S. Gov't, Review
- PMID
- 31003596
Original abstract
Circulating tumor (ct) DNA is a powerful tool that can be used to track cancer beyond a single snapshot in space and time. It has potential applications in detecting minimal residual disease and predicting relapse, in selecting patients for tailored treatments, and in revealing mechanisms of response or resistance. Here, we discuss the incorporation of ctDNA into clinical trials.